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Abstract
Background: This study investigated the relationship between changes in lung function (as measured by forced
expiratory volume in one second [FEV1]) and the St. George’s Respiratory Questionnaire (SGRQ) and economically
significant outcomes of exacerbations and health resource utilization, with an aim to provide insight into whether
the effects of COPD treatment on lung function and health status relate to a reduced risk for exacerbations.
Methods: A systematic literature review was conducted in MEDLINE, Embase, and the Cochrane Central Register of
Controlled Trials to identify randomized controlled trials of adult COPD patients published in English since 2002 in
order to relate mean change in FEV1 and SGRQ total score to exacerbations and hospitalizations. These predictor/
outcome pairs were analyzed using sample-size weighted regression analyses, which estimated a regression slope
relating the two treatment effects, as well as a confidence interval and a test of statistical significance.
Results: Sixty-seven trials were included in the analysis. Significant relationships were seen between: FEV1 and any
exacerbation (time to first exacerbation or patients with at least one exacerbation, p = 0.001); between FEV1 and
moderate-to-severe exacerbations (time to first exacerbation, patients with at least one exacerbation, or annualized
rate, p = 0.045); between SGRQ score and any exacerbation (time to first exacerbation or patients with at least one
exacerbation, p = 0.0002) and between SGRQ score and moderate-to-severe exacerbations (time to first exacerbation
or patients with at least one exacerbation, p = 0.0279; annualized rate, p = 0.0024). Relationships between FEV1 or SGRQ
score and annualized exacerbation rate for any exacerbation or hospitalized exacerbations were not significant.
Conclusions: The regression analysis demonstrated a significant association between improvements in FEV1 and SGRQ
score and lower risk for COPD exacerbations. Even in cases of non-significant relationships, results were in the expected
direction with few exceptions. The results of this analysis offer health care providers and payers a broader picture of the
relationship between exacerbations and mean change in FEV1 as well as SGRQ score, and will help inform clinical and
formulary-making decisions while stimulating new research questions for future prospective studies.
Keywords: COPD, Exacerbations, FEV1, SGRQ, Health resource utilization, Regression analysis
* Correspondence: amber.martin@evidera.com
1Evidera, 430 Bedford Street, Suite 300, 02420 Lexington, MA, USA
Full list of author information is available at the end of the article
© 2016 Martin et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Martin et al. Respiratory Research  (2016) 17:40 
DOI 10.1186/s12931-016-0356-1
Background
Chronic obstructive pulmonary disease (COPD) is char-
acterized by persistent airway obstruction related to
chronic inflammatory responses in the lungs with symp-
toms including disabling dyspnea, fatigue, and persistent
cough with excessive sputum. Exacerbations are charac-
terized by a sustained acute worsening of respiratory
symptoms beyond daily fluctuations, which leads to
changes in medication use. Due to the disease symp-
toms, COPD patients often have a reduced capacity for
physical activity and this may worsen potential systemic
manifestations of the disease, such as cardiovascular and
psychiatric comorbidities. The global prevalence of
COPD is estimated to be 9.2 % [1] with variable esti-
mates, ranging from 3.9 % [2] in the Netherlands to
20.9 % in the US, [3] when reported by country.
Therefore, COPD presents a major clinical and hu-
manistic burden, [4] despite the availability and use of
standard treatments, which aim to relieve symptoms and
slow disease progression [5].
This heavy disease toll inevitably focuses interest on
how patients are treated and the extent to which medi-
cations produce meaningful benefits. Assessment of such
value in clinical trials has traditionally relied on mea-
sures of lung function (such as forced expiratory volume
in one second [FEV1]), symptom control, health status,
and rates of exacerbation over a period of up to one
year. Exacerbations are a particularly important marker,
not least because they are a key driver of health resource
use (HRU), such as emergency department visits, anti-
biotic use and hospitalization. Evidence of this includes
the fact that an exacerbation can cost upwards of $7,000
each, depending on its severity and whether the patient
is hospitalized [6]. Unsurprisingly, payers tend to focus
on this outcome in their formulary considerations, with
the expectation that decreased exacerbation rates will
likely result in lower costs for their plan.
The clinical and economic importance of exacerba-
tions in COPD invites questions about their inter-
relationship with other well-established measures of
treatment effect. These include, for example, persistent
and/or uncontrolled disease symptoms and health status
as measured by the St. George’s Respiratory Question-
naire [SGRQ] – which captures symptoms, impact on
patient well-being, and activities of daily living. Add-
itionally, clinically relevant improvements in lung func-
tion measures such as FEV1, are often required by
regulators for certain drug approval processes. Of note,
previous studies have looked at the link between FEV1
and SGRQ score [7, 8] but their relationship to longer-
term outcomes, such as exacerbations and HRU, is not
well-known and/or accepted, and this may account for
why they have received comparatively less consideration
from clinicians and payers.
Against this background, the current study aimed to
investigate the relationship between changes in FEV1
and SGRQ score and economically significant outcomes
of exacerbations and HRU, by conducting a systematic
literature review (SLR) and regression analysis of rele-
vant studies of pharmacological interventions for COPD.
The results of this analysis will help the interpretation of
clinical trial results and provide insights into whether or
how the effects of COPD treatment seen in such studies
relate to long-term clinical benefits.
Methods
Literature review
Search strategy
We systematically reviewed MEDLINE- (via PubMed),
Embase-, and the Cochrane Central Register of Con-
trolled Trials (CENTRAL) -indexed literature published
from January 1, 2002 through October 1, 2014. The
search algorithms used keywords for COPD paired with
terms for the endpoints of interest–SGRQ, FEV1, exacer-
bations, and HRU. Limits included clinical trials on
humans published in English.
Study selection
Following the literature search, all titles and abstracts
identified from MEDLINE, Embase, and CENTRAL
were manually reviewed against the inclusion and exclu-
sion criteria using PICOS (Patient, Interventions, Com-
parisons, Outcomes, Study Design)-related elements.
Studies were required to report on at least 20 adult
COPD patients, to evaluate pharmacologic treatments
labeled for or intended for use as treatment of COPD
with any comparator treatment, to report mean change
in either FEV1 or SGRQ score and either COPD exacer-
bations or any HRU endpoint, and to be a randomized
controlled trial (RCT). A single investigator screened all
abstracts identified through the searches, according to
the specified inclusion and exclusion criteria. The full-
text articles of accepted studies that passed abstract
screening were retrieved for further review. Screening
was conducted by a single investigator using the same
inclusion and exclusion criteria that had been applied at
the abstract level. All excluded studies were confirmed
by a second, senior investigator and any discrepancies
between the two investigators were resolved by involve-
ment of a third investigator.
Data extraction process
The results of all accepted studies identified as part of
the SLR were extracted by a single investigator trained
in the critical assessment of evidence, with validation
performed by a senior investigator. Trial quality and risk
of bias were assessed during extraction for each included
study using the Jadad quality score assessment.
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Statistical analysis
The analyses relating measures of FEV1 and SGRQ total
score to exacerbations and HRU followed the meta-
analyses methods outlined by Johnson et al. [9] Each
trial supplied one or more pairs of data points on the
treatment effects of interest. These predictor/outcome
pairs from each of the studies were analyzed using
sample-size weighted regression analyses, which esti-
mated a regression slope relating the two treatment ef-
fects, as well as a confidence interval and a test of
statistical significance. In general, the predictor was a
relative treatment effect for change in SGRQ or trough
FEV1, and the outcome was a log-relative-risk or log-
rate for exacerbations. Pre-bronchodilator FEV1 was
considered as equivalent to trough FEV1 for analysis,
while post-bronchodilator measures and FEV1 that was
unspecified were not included. Primary analyses were
designed to avoid the use of an intercept in the regres-
sions, but fit was superior with an intercept included.
For the analyses of patients experiencing at least one
exacerbation, studies were included if they reported on ex-
acerbations of all severities. For analyses of patients experi-
encing at least one moderate-to-severe exacerbation,
studies were included if they reported on exacerbations
that required antibiotics, oral corticosteroids (OCS), and/
or hospitalization. Data on time to first exacerbation or the
number of patients with at least one exacerbation were
combined for analysis. COPD exacerbations reported as an
adverse event were not included in analysis. All studies
reporting data at timepoints ≥24 weeks were eligible for in-
clusion in the analyses. Separate analyses were conducted
for all timepoints ≥24 weeks and ≥48 weeks.
Results
Literature review
The literature review identified 67 trials reporting end-
points of interest at timepoints ≥24 weeks that were eli-
gible for inclusion in the regression analysis. Fig. 1
outlines the overall search hits and study attrition during
screening and analysis.
Regression analysis
In the figures representing the analyses, each point in
the plot represents a study comparison for two effects.
For instance, the point in the middle of Fig. 2 is from
Bateman et al. [10] and represents their findings in the
comparison of tiotropium 5 mg (via the Respimat® in-
haler) vs. placebo. In this example, the difference be-
tween the two treatments in trough FEV1 change was
-0.10, and the hazard ratio (HR) for any exacerbation
risk was 0.693 (for a log-HR of -0.37). Each study with
two arms (one treatment comparison, e.g. treatment A
Fig. 1 Study Attrition in the Systematic Literature Review
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vs. treatment B) and with sufficient data contributed one
data point to the analysis; studies with three arms (two
treatment comparisons, e.g. A vs. B and A vs. C) contrib-
uted two data points.
Any given slope can be interpreted by determining
what difference between treatments in log-exacerbation
risk one would expect given the difference in trough
FEV1 change. The predicted log-relative-risk of exacer-
bation in studies like Bateman 2010 is:
ln RRAnyExacerbationð Þ ¼ Intercept þ Slope
 Difference in trough FEV1change:
Or
ln RRAnyExacerbationð Þ ¼ 0:14 −3:56 0:10ð Þ;
¼ −0:22:
As exp (-0.22) = 0.80, we can predict that the relative risk
of exacerbation in studies like Bateman 2010 will be 20 %
lower for active treatment than for control. As noted above
and in the plot, in Bateman 2010 the relative risk of any ex-
acerbation was actually slightly lower than this value (0.693).
Relationships with exacerbations at ≥48 weeks
Forced Expiratory Volume in One Second (trough FEV1)
Mean Change in Trough FEV1 and COPD Patients’
Risk for Any Exacerbation The relationship between
relative treatment effects on change in FEV1 and any ex-
acerbation was of moderate strength and was statistically
significant (slope: -3.56, p = 0.0001; Fig. 2) when defining
the exacerbation outcome as time to first exacerbation
or the number of patients with at least one exacerbation.
No relationship was found (slope: 0.078, p = 0.9199)
between treatment effects on FEV1 and annualized ex-
acerbation rate. Figure 2 plots the relationship between
the mean difference in trough FEV1 and relative risk for
any exacerbation and Table 1 shows the raw trial data
contributing to this analysis.
Mean Change in Trough FEV1 and COPD Patients’
Risk for Moderate-to-Severe Exacerbations The rela-
tionship between relative treatment effects on change in
FEV1 and moderate-to-severe exacerbations was of mod-
erate strength and was statistically significant (slope:
-1.46, p = 0.045; Fig. 3) when defining the exacerbation
outcome either as time to first exacerbation, the number
of patients with at least one exacerbation, or as annualized
exacerbation rates. Figure 3 shows the relationship be-
tween the mean difference in trough FEV1 and the relative
risk for a moderate-to-severe exacerbation. Table 2 shows
the raw trial data contributing to this analysis.
St. George’s respiratory questionnaire
Mean Change in SGRQ Total Score and COPD
Patients’ Risk for Any Exacerbations The relationship
between relative treatment effects for change in SGRQ
score and any exacerbation was of moderate strength
(slope: 0.112, p = 0.0002; Fig. 4) and was statistically sig-
nificant when defining the exacerbation outcome as time
to first-exacerbation or the number of patients with at
least one exacerbation. The relationship was weaker and
not statistically significant (slope: 0.014, p = 0.2825)
when examining annualized exacerbation rates. Figure 4
shows the relationship between the mean difference in
SGRQ score and relative risk for any exacerbation and
Table 3 shows the raw trial data contributing to this analysis.
Fig. 2 Relationship between Mean Change in Trough FEV1 and Relative Risk for Any Exacerbation
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Table 1 Study Data for Trials Reporting Mean Change in Trough FEV1 and Patients Experiencing Any Exacerbation
Author,
Year
Treatment Time
point
(weeks)
N
Randomized
Definition of
exacerbation
Annual
exacerbation
rate
N with any
exacerbation
Comparison
data for Time
to first
exacerbation
(Hazard ratio)
Mean
change
in
Trough
FEV1 (L)
Comparison
data for
Trough FEV1
(treatment
difference)
Bateman,
2010 [10]
Tiotropium 5 ug 48 1989 B+ 0.12 685 Tio5 vs.
Placebo: 0.69
0.119 –
Placebo 48 2002 0.15 842 0.018 –
Calverley,
2010 [12]
Beclomethasone/formoterol
pMDI 400/24 μg
48 237 NR 0.074 64 – 0.077 B/F pMDI vs.
F-DPI: 0.051
Budesonide/formoterol
DPI)800/24 μg
48 242 0.033 64 – 0.08 B/F dry vs. F-
DPI: 0.053
Formoterol DPI 12 μg 48 239 0.04 66 – 0.026 –
Chapman,
2011 [13]
Indacaterol, 150 μg 52 420 A – – Ind150 vs.
Placebo: 0.82
0.12 –
Indacaterol, 300 μg 52 418 – – Ind300 vs.
Placebo: 0.86
0.13 –
Placebo 52 425 – – -0.04 –
Dahl, 2010
[14]
Indacaterol 300 μg 52 437 A – – Inda300 vs.
Placebo: 0.77
– Inda300 vs.
Placebo: 0.16
Indacaterol 600 μg 52 428 – – Inda600 vs.
Placebo: 0.69
– Inda600 vs.
Placebo: 0.15
Formoterol 52 435 – – F vs. Placebo:
0.77
– F vs.
Placebo: 0.05
Placebo 52 432 – – – –
Decramer,
2013 [15]
Tiotropium bromide 18 μg 26 1721 C – – Tio18 vs.
Inda150: 0.81
– Tio18 vs.
Inda150: 0.02
Indacaterol maleate 150 μg
once-daily
26 1723 – – – –
Tiotropium bromide 18 μg 52 1721 0.07 547 – 0.092 –
Indacaterol maleate 150 μg
once-daily
52 1723 0.1 619 – 0.073 –
Dusser,
2006 [16]
Tiotropium 18 μg
once daily
48 500 C – 248 – – –
Placebo 48 510 – 305 – – Tio18 vs.
Placebo: 0.12
Ferguson,
2008 [17]
Fluticasone propionate/
salmeterol (FSC) 250/50
52 394 C – 343 – -0.012 –
Salmeterol 50 μg 52 388 – 335 – -0.082 –
van
Grunsven,
2003 [18]
Fluticasone propionate
(Flixotides) 250 μg bid
103 24 D – 5 – -0.12 F250 vs.
Placebo: 0.06
Placebo bid 103 24 – 3 – -0.17 –
Vincken,
2002 [19]
Tiotropium 18 μg
qd in the morning
52 356 B – 125 – 0.12 –
Ipratropium 40 μg qid 52 179 – 82 – -0.03 –
Wouters,
2005 [20]
Salmeterol/fluticasone
(3 month run in period of
salmeterol 50 μg and
fluticasone 500 μg bid)
52 189 E – 115 – -0.04 S/F vs. S:
0.05
Salmeterol (3 month run in
period of salmeterol 50 μg
and fluticasone 500 μg bid)
52 184 – 109 – -0.1 –
Zhou,
2006 [21]
Theophylline 52 57 C – 26 – 0.0063 –
Placebo 52 53 – 30 – -0.0533 –
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Mean Change in SGRQ Total Score and COPD
Patients’ Risk for Moderate-to-severe Exacerbations
The relationship between relative treatment effects for
change in SGRQ score and a moderate-to-severe exacer-
bation was of moderate strength and was statistically sig-
nificant when defining the exacerbation outcome as
either the number of patients with at least one
exacerbation (slope: 0.046, p = 0.0279, Fig. 5) or as an
annualized exacerbation rate (slope: 0.056, p = 0.0024,
figure not shown). Figure 5 shows the relationship be-
tween the mean difference in SGRQ score and the rela-
tive risk for a moderate-to-severe exacerbation and
Table 4 shows the raw trial data contributing to this
analysis.
Table 1 Study Data for Trials Reporting Mean Change in Trough FEV1 and Patients Experiencing Any Exacerbation (Continued)
Dransfield,
2013 [22]
Vilanterol 25 μg 52 409 A – 203 – -0.04 –
Fluticasone furoate 50 μg +
Vilanterol 25 μg
52 408 – 190 – 0 –
Fluticasone furoate 100 μg
+ Vilanterol 25 μg
52 403 – 161 – 0.02 –
Fluticasone furoate 200 μg
+ Vilanterol 25 μg
52 402 – 178 – 0.02 –
Vilanterol 25 μg 52 409 – 197 – -0.02 –
Fluticasone furoate 50 μg +
Vilanterol 25 μg
52 412 – 198 – 0.02 –
Fluticasone furoate 100 μg
+ Vilanterol 25 μg
52 403 – 177 – 0.01 –
Fluticasone furoate 200 μg
+ Vilanterol 25 μg
52 409 – 160 – 0.01 –
Exacerbation Definitions:
A:Symptom deterioration requiring antibiotics, systemic corticosteroids, and/or hospitalization
B:A complex of respiratory events lasting ≥3 days
B+:A complex of respiratory events lasting ≥3 days requiring treatment
C:Worsening of at least two symptoms for at least two days
D:Having two of the following three symptoms: increased cough, wheezing and/or dyspnea; change in sputum color; use of bronchodilator rescue medication
E:If a patient has in ≥2 consecutive days used ≥3 extra inhalations of salbutamol per 24 hours above their reference rescue value
– = Not Reported
Fig. 3 Relationship between Mean Change in Trough FEV1 and Risk for a Moderate-to-Severe Exacerbation
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Table 2 Study Data for Trials Reporting Mean change in FEV1 and Patients Experiencing Moderate-to-Severe COPD Exacerbation
Author, Year Treatment Time
point
(weeks)
N Randomized Annual
exacerbation
rate (M-S)
N with M-S
exacerbation
Comparison
data for
Time to first
exacerbation
(Hazard ratio)
Mean
change
in Trough
FEV1 (L)
Comparison
data for Trough
FEV1
(treatment
difference)
Anzueto,
2009 [23]
Fluticasone propionate/
salmeterol 250 mcg/50
mcg bid
52 394 1.1 208 FP250 + S50 vs.
S50: 0.73
-0.017 –
Salmeterol 50 mcg bid 52 403 1.59 234 – -0.097 –
Bateman,
2010 [10]
Tiotropium 5 μg orally
inhaled once daily
48 670 0.93 249 – 0.08 Tio5 vs.
Placebo: 0.127
Tiotropium 10 μg orally
inhaled once daily
48 667 1.02 246 – 0.11 Tio10 vs.
Placebo: 0.150
Placebo 48 653 1.91 288 – -0.04
Dahl, 2010
[14]
Indacaterol 300 μg 52 437 0.6 133 – – Inda300 vs.
Placebo: 0.16
Indacaterol 600 μg 52 428 0.57 116 – – Inda600 vs.
Placebo: 0.15
Formoterol 52 435 0.56 126 – – F vs. Placebo: 0.05
Placebo 52 432 0.74 145 – –
Donohue,
2014 [24]
UMEC/VI 125/25 mcg 52 226 – 30 UMEC/VI vs.
Placebo: 0.6
0.18 UMEC/VI vs.
Placebo: 0.231
UMEC 125 mcg 52 227 – 34 UMEC vs.
Placebo: 0.4
0.13 UMEC vs.
Placebo: 0.178
Placebo 52 109 – 26 – -0.05 –
Ferguson,
2008 [17]
Fluticasone propionate/
salmeterol (FSC) 250/50
52 394 1.06 211 FP/S vs. S: 0.75 -0.012 –
Salmeterol 50 μg 52 388 1.53 230 – -0.082 –
Kerwin,
2012 [25]
NVA237 50 μg qd 52 529 0.54 NVA vs.
Placebo: 0.66
0.112 NVA vs.
Placebo: 0.108
Tiotropium 18 μg qd 52 268 – – NVA vs. Tio: 1.1 0.092 NVA vs. Tio: 0.019
Placebo 52 269 0.8 – – -0.097
Sharafkhaneh,
2012 [26]
Budesonide/formoterol
pMDI 160/4.5 μg x 2
inhalations bid (320/9 μg)
52 407 0.867 169 – 0.07 –
Budesonide/formoterol
pMDI 80/4.5 μg x 2
inhalations bid (160/9 μg)
52 408 0.952 173 – 0.07 –
Formoterol DPI 4.5 μg x 2
inhalations bid (9 μg)
52 404 1.171 182 – 0.04 –
Tang, 2013
[27]
Tiotropium 5 μg
(2 x 2.5 μg/puff)
48 167 – 58 Tio5 vs.
Placebo: 0.54
– Tio5 vs.
Placebo: 0.134
Placebo (2 puffs) 48 171 – 83 – – –
Tashkin, 2008
[11]
Tiotropium 18 μg once
daily; followed by 40 μg
of ipratropium four times
daily for 30 days after
4 years of treatment.
206 2987 – 2001 – 0.03 –
Placebo once daily;
followed by 40 μg of
ipratropium four times
daily for 30 days after
4 years of treatment.
206 3006 – 2049 – -0.05 –
Calverley,
2009 [28]
Roflumilast 500 mcg
once per day
52 765 1.08 344 ROLF500 vs.
Placebo
(Trial 1): 0.88
0.046 ROLF500 vs.
Placebo
(Trial 1): 0.039
Martin et al. Respiratory Research  (2016) 17:40 Page 7 of 15
Table 2 Study Data for Trials Reporting Mean change in FEV1 and Patients Experiencing Moderate-to-Severe COPD Exacerbation (Continued)
Placebo 52 758 1.27 389 – 0.008 –
Roflumilast 500 mcg once
per day
52 772 1.21 373 ROLF500 vs.
Placebo
(Trial 2): 0.89
0.033 ROLF500 vs.
Placebo
(Trial 2): 0.058
Placebo 52 796 1.49 432 – -0.025 –
Dransfield,
2013 [22]
Vilanterol 25 μg 52 409 1.05 – FF200 + V vs.
V: 0.9
-0.04 –
Fluticasone furoate 50 μg
+ Vilanterol 25 μg
52 408 0.92 – FF100 + V vs.
V: 0.7
0 –
Fluticasone furoate
100 μg + Vilanterol 25 μg
52 403 0.7 – FF50 + V vs.
V: 0.9
0.02 –
Fluticasone furoate
200 μg + Vilanterol 25 μg
52 402 0.9 – – 0.02 –
Vilanterol 25 μg 52 409 1.14 – FF200 + V vs.
V: 0.7
-0.02 –
Fluticasone furoate 50 μg
+ Vilanterol 25 μg
52 412 0.92 – FF100 + V vs.
V: 0.8
0.02 –
Fluticasone furoate
100 μg + Vilanterol 25 μg
52 403 0.9 – FF50 + V vs.
V: 0.9
0.01 –
Fluticasone furoate
200 μg + Vilanterol 25 μg
52 409 0.79 – – 0.01 –
Jones,
2011 [29]
Aclidinium 200 μg 52 627 167 Aclid200 vs.
Placebo
(Trial 1): 0.00
-0.013
Placebo 52 216 0.46 55 – -0.065 –
Aclidinium 200 μg 52 600 199 – -0.009 –
Placebo 52 204 0.8 81 – -0.024 –
M-S = moderate-to-severe
– = Not reported
Fig. 4 Relationship between Mean Change in SGRQ Total Score and Risk for Any Exacerbation
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Table 3 Study Data for Trials Reporting Mean change in SGRQ Total Score and Patients Experiencing Any COPD Exacerbation
Author,
year
Treatment Time
point
(weeks)
N
Randomized
Definition of
exacerbation
Annual
exacerbation
rate (any)
N with any
exacerbation
Comparison
data for
Time to first
exacerbation
(Hazard ratio)
Mean
change
in SGRQ
Total Score
Comparison
data for SGRQ
(treatment
difference)
Bateman,
2010 [10]
Tiotropium 5 μg 48 1989 B+ 0.69 685 Tio vs.
placebo: 0.93
-4.7 Tio5 vs.
placebo: -2.9
Placebo 48 2002 0.87 842 -1.8 –
Calverley,
2003 [30]
Budesonide/formoterol
320/9 mg (bid)
52 254 A 1.38 – B + F vs.
B: 0.77
– B + F vs. B: -4.5
Budesonide 400 mg
(bid)
52 257 1.6 – B + F vs.
F: 0.71
– B + F vs. F: -3.4
Formoterol 9 mg (bid) 52 255 1.85 – B + F vs.
Placebo: 0.72
– B + F vs.
Placebo: -7.5
Placebo 52 256 1.8 – – – –
Calverley,
2010 [12]
Beclomethasone/
formoterol pMDI
400/24 μg
48 237 NR 0.414 64 – -3.75 –
Budesonide/formoterol
DPI 800/24 μg
48 242 0.423 64 – -4.28 –
Formoterol DPI 12 μg 48 239 0.431 66 – -2.9 –
Casaburi,
2002 [31]
Tiotropium 18 μg 52 550 B 0.76 198 – -3.2 –
Placebo 52 371 0.95 156 – 0.5 –
Chapman,
2011 [13]
Indacaterol, 150 μg 52 420 A – – Ind150 vs.
Placebo: 0.82
-7.5 –
Indacaterol, 300 μg 52 418 – – Ind300 vs.
Placebo: 0.86
-5.5 –
Placebo 52 425 – – – -5.5 –
Dahl, 2010
[14]
Indacaterol 300 μg 52 437 A – – Inda300 vs.
Placebo: 0.77
-6.5 Inda300 vs.
Placebo: -4.7
Indacaterol 600 μg 52 428 – – Inda600 vs.
Placebo: 0.69
-7.2 Inda600 vs.
Placebo: -4.6
Formoterol 52 435 – – F vs.
Placebo: 0.77
-7 F vs. Placebo: -4
Placebo 52 432 – – – -1.7 –
Decramer,
2013 [15]
Tiotropium bromide
18 μg
26 1721 C – – – -5.2 –
Indacaterol maleate
150 μg once-daily
26 1723 – – – -4.5 –
Tiotropium bromide
18 μg
52 1721 0.61 547 – -4.9 –
Indacaterol maleate
150 μg once-daily
52 1723 0.79 619 – -4.5 –
Ferguson,
2008 [17]
Fluticasone propionate/
salmeterol (FSC) 250/50
52 394 C 4.82 343 – -3.49 FP/S vs. S: -1.86
Salmeterol 50 μg 52 388 5.78 335 – -1.86 –
Vincken,
2002 [19]
Tiotropium 18 μg qd in
the morning
52 356 B 0.73 125 – -3.74 Tio18 vs.
Ipra40: -3.3
Ipratropium 40 μg qid 52 179 0.96 82 – -0.44 –
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Relationship between FEV1 and SGRQ and Hospitalized
COPD Exacerbations
There were insufficient data to analyze association with all-
cause hospitalizations, and the annualized and patient-level
data were combined for the analysis of hospitalizations due
to exacerbations. Additionally, relative effects for the num-
ber of patients with an exacerbation were combined with
annualized exacerbation rates to facilitate analyses.
FEV1 and SGRQ
For both SGRQ score and FEV1, the plots indicate a
somewhat weaker relationship with exacerbations
resulting in hospitalization (compared to the findings
for exacerbations overall). Results were not statisti-
cally significant (FEV1 slope: -1.49, p-value = 0.174
[Fig. 6]; SGRQ slope: 0.0518, p = 0.126 [Fig. 7]) for
either relationship.
Table 3 Study Data for Trials Reporting Mean change in SGRQ Total Score and Patients Experiencing Any COPD Exacerbation
(Continued)
Wedzicha,
2014 [32]
beclomethasone
dipropionate/formoterol
fumarate (BDP/FOR) 100/
6 μg, 2 inhalations BID
48 602 F 0.8 264 BDP + F vs.
F: 0.8
-3.55 BDP/F vs.
F: -2.78
Formoterol fumarate
(FOR) 12 μg, 1
inhalation BID
48 597 1.12 294 – -0.77 –
Wouters,
2005 [20]
Salmeterol/fluticasone
(3 month run in period
of salmeterol 50 μg and
fluticasone 500 μg bid)
52 189 E – 115 – 2.4 S/F vs. S: -0.89
Salmeterol (3 month
run in period of
salmeterol 50 μg and
fluticasone 500 μg bid)
52 184 – 109 – 3.2 –
Exacerbation Definitions:
A:Symptom deterioration requiring antibiotics, systemic corticosteroids, and/or hospitalization
B:A complex of respiratory events lasting ≥3 days
B+:A complex of respiratory events lasting ≥3 days requiring treatment
C:Worsening of at least two symptoms for at least two days
E:If a patient has in ≥2 consecutive days used ≥3 extra inhalations of salbutamol per 24 hours above their reference rescue value
F:An acute event characterized by a worsening of the patient's respiratory symptoms that is beyond normal day-to-day variations and leads to a change in medication
– = Not reported
Fig. 5 Relationship between Mean Change in SGRQ Total Score and Risk for a Moderate-to-severe Exacerbation
Martin et al. Respiratory Research  (2016) 17:40 Page 10 of 15
Table 4 Study Data for Trials Reporting Mean change in SGRQ Total Score and Patients Experiencing Moderate-to-severe COPD
Exacerbation
Author,
Year
Treatment Time
point
(weeks)
N
Randomized
Annual
exacerbation
rate (M-S)
N with M-S
exacerbation
Comparison
data for
Time to first
exacerbation
(Hazard ratio)
Mean change
in SGRQ
Total Score
Comparison
data for SGRQ
(treatment
difference)
Anzueto,
2009 [23]
Fluticasone propionate/
salmeterol 250 mcg/50 μg bid
52 394 1.1 208 FP250 + S50 vs.
S50: 0.73
2.49 FP250 + S50 vs.
S50: -0.81
Salmeterol 50 μg bid 52 403 1.59 234 – 3.28 –
Bateman,
2010 [20]
Tiotropium 5 μg orally inhaled
once daily
48 670 0.93 249 – -5.1 Tio5 vs.
Placebo: -3.5
Tiotropium 10 μg orally inhaled
once daily
48 667 1.02 246 – -5.5 Tio10 vs.
Placebo: -3.8
Placebo 48 653 1.91 288 – -1.6 –
Dahl, 2010
[14]
Indacaterol 300 μg 52 437 0.6 133 – -6.5 Inda300 vs.
Placebo: -4.7
Indacaterol 600 μg 52 428 0.57 116 – -7.2 Inda600 vs.
Placebo: -4.6
Formoterol 52 435 0.56 126 – -7 F vs. Placebo: -4
Placebo 52 432 0.74 145 – -1.7 –
Ferguson,
2008 [17]
Fluticasone propionate/
salmeterol (FSC) 250/50
52 394 1.06 211 FP + S vs. S: 0.75 -3.49 FP/S vs. S: -1.86
Salmeterol 50 μg 52 388 1.53 230 – -1.86 –
Hagedorn,
2013 [33]
Salmeterol xinafoate/
fluticasone propionate via a
single inhaler (SFC)
52 108 0.81 42 – -1.8 –
Salmeterol xinafoate/
fluticasone propionate via
separate inhalers (Sal/FP)
52 106 0.98 44 – -2.6 –
Kerwin,
2012 [25]
NVA237 50 μg qd 52 529 0.54 – NVA vs.
Placebo: 0.66
– NVA vs.
Placebo: -3.32
Tiotropium 18 μg qd 52 268 – NVA vs. Tio: 1.1 – NVA vs.
Tio: -0.48
Placebo 52 269 0.8 – – – –
Sharafkhaneh, 2012 [26] Budesonide/
formoterol
pMDI 160/
4.5 μg x 2
inhalations
bid (320/9 μg)
52 407 0.867 169 –
-7.2 –
Budesonide/
formoterol
pMDI 80/
4.5 μg x 2
inhalations
bid (160/9 μg)
52 408 0.952 173 –
-5.5 –
Formoterol DPI 4.5 μg
x 2 inhalations bid (9 μg)
52 404 1.171 182 – -5.9 –
Tang,
2013 [27]
Tiotropium 5 μg
(2 x 2.5 μg/puff)
48 167 – 58 Tio5 vs.
Placebo: 0.54
-7.1 Tio5 vs.
Placebo: -3.9
Placebo (2 puffs) 48 171 – 83 – -3.3 –
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Impact of including All timepoints >24 weeks
Expanding the data set from outcomes reported at >48 weeks
to include outcomes reported at >24 weeks showed similar
directionality but weaker results compared with the long-
term analysis data of both SGRQ score and FEV1 (data not
shown).
Discussion
Our systematic literature review and regression analysis
demonstrated that beneficial mean change in either FEV1
or SGRQ total score was associated with a lower risk for
exacerbations. Specifically, it showed that in randomized
trials of COPD drug treatments lasting ≥48 weeks, there
Table 4 Study Data for Trials Reporting Mean change in SGRQ Total Score and Patients Experiencing Moderate-to-severe COPD Ex-
acerbation (Continued)
Tashkin,
2008 [11]
Tiotropium 18 μg once daily;
followed by 40 μg of
ipratropium four times daily
for 30 days after 4 years of
treatment.
206 2987 – 2001 – -1.25 –
Placebo once daily; followed
by 40 μg of ipratropium four
times daily for 30 days after
4 years of treatment.
206 3006 – 2049 – -1.21 –
Wedzicha,
2008 [34]
Salmeterol 50 μg + fluticasone
propionate 500 μg bid
104 658 – 408 – -1.7 –
Tiotropium bromide 18 μg
once daily
104 665 – 392 – 0.37 S + F vs.
Tio18: -2.07
Jones,
2011 [29]
Aclidinium 200 μg 52 627 – 167 Aclid200 vs.
Placebo
(trial 1): 1.00
– Aclid200 vs.
Placebo
(trial 1): -1.53
Placebo 52 216 – 55 – – –
Aclidinium 200 μg 52 600 – 199 – – Aclid200 vs.
Placebo
(trial 2): -2.21
Placebo 52 204 – 81 – – –
M-S = moderate-to-severe
– = Not reported
Fig. 6 Relationship between Mean Change in FEV1 and Risk for Hospitalization
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was generally a relationship between relative efficacy in
improving FEV1 and SGRQ total score and relative effi-
cacy for lowering exacerbation risk. The majority of ana-
lyses showed the same trend towards a relationship
between positive changes in FEV1 and SGRQ score and
exacerbation risk, even though results did not always
reach statistical significance. Of note, there was no rela-
tionship shown between mean change in FEV1 and annu-
alized exacerbation rate, despite this relationship being
moderate and statistically significant when the risk of ex-
periencing at least one exacerbation in patients was ana-
lyzed. The mean change in SGRQ total score was not
significantly related to the rate of exacerbations across all
severities but had a moderate, statistically significant rela-
tionship with the rate of moderate-to-severe exacerba-
tions. The relationship between FEV1 and SGRQ score
and hospitalizations was less clear, and further research is
needed in this area.
To our knowledge, the literature review and regression
analysis we conducted is the first such study to evaluate
the inter-relationship that health status and lung func-
tion have with exacerbation risk. It provides a more
rigorous examination of a relationship between labora-
tory values and exacerbations than has been done in the
past, as, unlike former studies, it correlates relative treat-
ment effects instead of absolute ones, thus lowering the
possibility of ecological bias. However, as this analysis
used only aggregated patient data from published trials,
we cannot assume that any statistical association ob-
served between arm-level variables may be translated to
patient-level associations. Therefore, our findings cannot
be used to predict any outcome at the patient-level.
Additionally, our analysis may be limited by the available
data for the surrogate measures given the trials reported
FEV1 in several different ways. Since our analysis was
limited to trough or prebronchodilator FEV1 data, ana-
lysis using other measures of FEV1 could yield different
results. Similarly, regarding exacerbation severity, we
categorized exacerbations based on the definitions re-
ported by study authors using a standardized approach
as defined in our methods section. However, in some
cases definitions were not reported so we relied on
author-defined groupings of any or moderate-to-severe
exacerbations.
Our research may have important implications for
regulatory assessment of drugs intended to help reduce
the risk of exacerbations in COPD and, in particular, the
evidence considered in such deliberations. Currently, to
gain marketing approval for this indication, such treat-
ments have to be tested in long-term, parallel trials,
which represent a logistic and economic burden on the
sponsoring organization. Because of this, few trials of
COPD drugs are powered to identify a significant differ-
ence in the reduced risk of exacerbations. It is for this
reason that to date very few drugs have been approved
for reducing exacerbations on the basis of prospective
1–2 year parallel trials, usually in patients with history of
acute exacerbations in the prior year. Our study suggests
changes in FEV1 and SGRQ might serve as reliable sur-
rogate markers of patients’ likelihood of experiencing an
Fig. 7 Relationship between Mean Change in SGRQ and Risk for Hospitalization
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exacerbation. If so, these measures could allow future
trials to be shorter and more manageable while still of-
fering key insights into treatments’ longer-term efficacy.
Since exacerbations can be costly to health plans, payers
should consider the effect of medications on these surro-
gate markers, even when long-term RCTs cannot be car-
ried out. Also, confirmation of our results would
broaden the application of data already available from
published shorter-term studies. This is especially import-
ant since the trials used to inform regulatory approval
were powered on each specific drug’s expected effect on
the acute exacerbation rate and all but one [11] were
small and had very selective entry criteria. This contrasts
with the trials contributing data for our review and ana-
lysis, since these were broader and more inclusive
(e.g. with regards to disease duration and reversibility,
comorbidities, interventions, and concomitant therapies)
and collectively more representative of the general
COPD population seen in everyday clinical practice.
Therefore, these collated data sources potentially
allow more generalizable conclusions to be drawn
regarding whether or how standard short-term end-
points assessed in trials relate to effects on
exacerbations.
Conclusions
In conclusion, this study demonstrates a significant associ-
ation between improvements in FEV1 and SGRQ total
score and lower risk for COPD exacerbations. We believe
that the results of our study offer providers and payers a
more informed picture of the inter-relationship between
exacerbations and both FEV1 and SGRQ score, which will
aid clinical and formulary decisions while stimulating re-
search questions for future prospective studies.
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